B7.2 Expressed by T Cells Does Not Induce CD28-Mediated Costimulatory Activity but Retains CTLA4 Binding: Implications for Induction of Antitumor Immunity to T Cell Tumors

Journal of Immunology

Volumn 158, Issue 5, 1997, Pages 2025-2034

  Greenfield, Edward A ^a,b,f   Howard, Edward ^b   Paradis, Timothy ^c   Nguyen, Khuong ^a   Benazzo, Franco ^b   McLean, Paul ^d   Höllsberg, Per ^b   Davis, Geoff ^e   Hafler, David A ^b   Sharpe, Arlene H ^a   Freeman, Gordon J ^a   Kuchroo, Vijay K ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c PFIZER INC   (United States)

^d TUFTS UNIVERSITY   (United States)

^e CELL GENESYS INC   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ANTIBODY CONJUGATE; CD28 ANTIGEN; CD86 ANTIGEN; CD86 PROTEIN, MOUSE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T-LYMPHOCYTE ANTIGEN 4; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BIOSYNTHESIS; C57BL MOUSE; CELL CULTURE; CELL DIVISION; FEMALE; GENETIC TRANSFECTION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MOUSE; PHYSIOLOGY; PROTEIN BINDING; T LYMPHOCYTE; THYMOMA;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD28; ANTIGENS, CD86; ANTIGENS, DIFFERENTIATION; CELL DIVISION; FEMALE; IMMUNOCONJUGATES; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PROTEIN BINDING; T-LYMPHOCYTES; THYMOMA; THYMUS NEOPLASMS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0031092641     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Boussiotis, V. A., J. G. Gribben, G. F. Freeman, and L. M. Nadler. 1994. Blockade of the CD28 co-stimulatory pathway: a means to induce tolerance. Curr. Opin. Immunol. 6:797.
2. Gimmi, C. D., G. J. Freeman, J. G. Gribben, G. Gray, and L. M. Nadler. 1993. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc. Natl. Acad. Sci. USA 90:6586.
3. Correy, D. B., S. L. Reiner, P. S. Linsley, and R. M. Locksley. 1994. Differential effects of blockade of CD28-B7 on the development of Th1 or Th2 effector cells in experimental leishmaniasis. J. Immunol. 153:4142.
4. Freeman, G. J., V. A. Boussiotis, A. Anumanthan, G. M. Bernstein, X. Y. Ke, P. D. Rennert, G. S. Gray, J. G. Gribben, and L. M. Nadler. 1995. B7.1 and B7.2 do not deliver identical costimulatory signals, since B7.2 but not B7.1 preferentially costimulates the initial production of IL-4. Immunity 2:523.
5. Kuchroo, V. K., M. P. Das, J. A. Brown, A. M. Ranger, S. S. Zamvil, R. A. Sobel, H. L. Weiner, N. Nabavi, and L. H. Glimcher. 1995. B7.1 and B7.2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 80:707.
6. Prabhu Das, M., S. S. Zamvil, F. Boriello, H. L. Weiner, A. H. Sharpe, and V. K. Kuchroo. 1995. Reciprocal expression of co-stimulatory molecules. B7.1 and B7.2, on murine T cells following activation. Eur. J. Immunol. 25:207.
7. Azuma, M., H. Yssel, J. H. Phillips, H. Spits, and L. L. Lanier. 1993. Functional expression of B7/BB1 on activated T lymphocytes. J. Exp. Med. 177:845.
8. Sansom, D. M., and N. D. Hall. 1993. B7/BB1, the ligand for CD28, is expressed on repeatedly activated human T cells in vitro. Eur. J. Immunol. 23:295.
9. Gribben, J. G., G. J. Freeman, V. A. Boussiotis, P. Rennert, C. L. Jellis, E. Greenfield, M. Barber, V. A. Restivo, Jr., X. Ke, G. S. Gray, and L. M. Nadler. 1995. CTLA-4 mediates antigen-specific apoptosis of human T cells. Proc. Natl. Acad. Sci USA 92:811.
10. Walunas, T. L., D. J. Lenschow, C. Y. Bakker, P. S. Linsley, G. J. Freeman, J. M. Green, C. B. Thompson, and J. A. Bluestone. 1994. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1:405.
11. Tivol, E. A., F. Boriello, A. N. Schweitzer, W. P. Lynch, J. A. Bluestone, and A. H. Sharpe. 1995. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3:541.
12. Waterhouse, P., J. M. Penninger, E. Timms, A. Wakeham, A. Shahinian, K. P. Lee, C. B. Thompson, H. Griesser, and T. W. Mak. 1995. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 270:985.
13. Finck, B. K., P. S. Linsley, and D. Wofsy. 1994. Treatment of murine lupus with CTLA-4-Ig. Science 265:1225.
14. Lenschow, D. J., S. C. Ho, H. Sattar, L. Rhee, G. Gray, N. Nabavi, K. C. Herold, and J. A. Bluestone. 1995. Differential effects of anti-B7.1 and anti-B7.2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J. Exp. Med. 181:1145.
15. Sayegh, M. H., E. Akalin, W. W. Hancock, M. E. Russell, C. B. Carpenter, P. S. Linsley, and L. A. Turka. 1995. CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J. Exp. Med. 181:1869.
16. Turka, L. A., P. S. Linsley, H. Lin, W. Brady, J. M. Leiden, R.-Q. Wei, M. L. Gibson, X.-G. Zheng, S. Myrdal, D. Gordon, T. Bailey, S. F. Bolling, and C. B. Thompson. 1992. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc. Natl. Acad. Sci. USA 89:11102.
17. Townsend, S. E., F. W. Su, J. M. Atherton, and J. P. Allison. 1994. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res. 54:6477.
18. Chen, L., S. Ashe, W. A. Brady, I. Hellstrom, K. E. Hellstrom, J. A. Ledbetter, P. McGowan, and P. S. Linsley. 1992. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71:1093.
19. Chen, L., P. McGowan, S. Ashe, J. Johnston, Y. Li, I. Hellstrom, and K. E. Hellstrom. 1994. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J. Exp. Med. 179:523.
20. + cytotoxic T lymphocytes in the absence of exogenous help. J. Exp. Med. 177:1791.
21. + T cells by B7-transfected melanoma cells. Science 259:368.
22. Baskar, S., S. Ostran-Resenberg, N. Nabavi, L. M. Nadler, G. J. Freeman, and L. H. Glimcher. 1993. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc. Natl. Acad. Sci. USA 90:5687.
23. Ramarathinam, L., M. Castle, Y. Wu, and Y. Liu. 1994. T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells. J. Exp. Med. 179:1205.
24. Yang, G., K. E. Hellstrom, I. Hellstrom, and L. Chen. 1995. Antitumor immunity elicited by tumor cells transfected with B7.2, a second ligand for CD28/CTLA-4 costimulatory molecules. J. Immunol. 154:2794.
25. Lanier, L. L., S. O'Fallon, C. Somoza, J. H. Phillips, P. S. Linsley, K. Okumura, D. Ito, and M. Azuma. 1995. CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL. J. Immunol. 154:97.
26. + T lymphocytes in the P815 tumor system in vitro. J. Immunol. 156:465.
27. Matulonis, U., C. Dosiou, G. Freeman, C. Lamont, P. Mauch, L. M. Nadler, and J. D. Griffin. 1996. B7.1 is superior to B7.2 costimulation in the induction and maintenance of T cell-mediated anti-leukemia immunity. J. Immunol. 156:1126.
28. Freeman, G. J., F. Borriello, R. J. Hodes, H. Reiser, J. G. Gribben, J. W. Ng, J. Kim, J. M. Goldberg, K. Hathcock, G. Laszlo, L. A. Lombard, S. Wang, G. S. Gray, L. M. Nadler, and A. H. Sharpe. 1993. Uncovering of functional alternative CTLA-4 counter receptor in B7-deficient mice. Science 262:907.
29. Freeman, G. J., F. Boriello, R. J. Hodes, H. Reiser, J. G. Gribben, J. W. Ng, J. Kim, J. M. Goldberg, K. Hathcock, G. Laszlo, L. A. Lombard, S. Wang, G. S. Gray, L. M. Nadler, and A. H. Sharpe. 1993. Murine B7-2, an alternative CTLA-4 counter-receptor that costimulates T cell proliferation and interleukin 2 production. J. Exp. Med. 178:2185.
30. Chen, C., and N. Nabavi. 1994. In vitro induction of T cell anergy by blocking B7 and early T cell costimulatory molecule ETC-1/B7.2. Immunity 1:147.
31. Krummel, M. F., and J. P. Allison. 1995. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182:459.
32. Boussiotis, V. A., G. J. Freeman, J. G. Gribben, J. Daley, G. Gray, and L. M. Nadler. 1993. Activated human B lymphocytes express three CTLA-4 counter-receptors that costimulate T-cell activation. Proc. Natl. Acad. Sci. USA 90:11059.
33. Hathcock, K. S., G. Laszlo, C. Pucillo, P. Linsley, and R. J. Hodes. 1994. Comparative analysis of B7.1 and B7.2 costimulatory ligands: expression and function. J. Exp. Med. 180:631.
34. Linsley, P. S., J. L. Greene, W. Brady, J. Bajorath, J. A. Ledbetter, and R. Peach. 1994. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1:793.
35. Denfield, R. W., A. Dietrich, C. Wuttig, E. Tanczos, J. M. Weiss, W. Vanscheidt, E. Schopf, and J. C. Simon. 1995. In situ expression of B7 and CD28 receptor families in human malignant melanoma: relevance for T-cell-mediated anti-tumor immunity. Int. J. Cancer 62:259.
36. Hodge, J. W., S. Abrams, J. Schlom, and J. A. Kantor. 1994. Induction of anti-tumor immunity by recombinant vaccinia viruses expressing B7.1 or BV.2 costimulatory molecules. Cancer Res. 54:5552.
37. Linsley, P. S. 1995. Distinct roles for CD28 and cytotoxic T lymphocyte-associated molecule-4 receptors during T cell activation. J. Exp. Med. 182:289.
38. Eardley, D. D., J. Hugenberger, L. McVay-Boudreau, F. W. Shen, R. K. Gershon, and H Cantor. 1978. Immunoregulatory circuits among T-cell sets. I. T-helper cells induce other T-cells to exert feedback inhibition. J. Exp. Med. 147:1106.
39. + T cells expressing Vβ8 TCR: a role of the Qa-1 molecule. Immunity 2:185.